SNAI1 and Myocardial fibrosis: The MCT1 inhibitor CHC can alleviate lactate-induced Snail1 lactylation and activation of TGF-β/Smad2 after hypoxia, reducing endothelial-to-mesenchymal transition, myocardial fibrosis, and cardiac dysfunction post-myocardial infarction [67].